Structural optimization of Schistosoma mansoni aspartyl protease inhibitors: integration of computational and experimental methods

Vol. 1, 2019 - 109006
Poster only
Favorite this paper
How to cite this paper?
Abstract

Schistosomiasis is caused by trematodes of the genus Schistosoma. Aspartyl proteases are essential in the life cycle of these parasites and are under investigation as drug targets. Several compounds with schistosomicidal activity have been identified using computational methods1,2. Previously our group has identified two compounds by virtual and experimental screening as potential inhibitors of S. mansoni cathepsin D-like1 enzyme (SmCD1). Aiming to find more potent inhibitors, a search on commercial small molecule databases was made for identifying compounds with better molecular docking results and ADMETox properties. Thirty-one compounds were tested for cytotoxicity in vitro on human kidney WSS1. Most of CC50 values were higher than 100 μM, indicating the safety at the cellular level. Currently, an experimental screening is being performed in the adult worm aqueous extract and in the recombinant SmCD1 enzyme. Most promising compounds will be tested on immature and adult stages of S. mansoni parasites ex vivo.

Track
  • 1. Strategies in Drug Design
Keywords
Drug Discovery
aspartic protease
Schistosomiasis